Blood Res.  2013 Sep;48(3):171-177. 10.5045/br.2013.48.3.171.

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party

• Suh C
• Kim WS
• Kim JS
• Park BB

• KMID: 2270702
• DOI: http://doi.org/10.5045/br.2013.48.3.171

Abstract

The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.

Keyword

Lymphoma; KSH; Lymhoma working party; CISL

MeSH Terms

Antibodies, Monoclonal, Murine-Derived
Hematology
Humans
Insurance, Health
Korea
Lymphoma
Lymphoma, B-Cell
Rituximab
Antibodies, Monoclonal, Murine-Derived

Figure

• 

  Fig. 1 Chronological flow of prospective CISL studies. Abbreviations: DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; OAML, ocular adnexa MZL; ENNKTCL, extranodal NK/T cell lymphoma; T-cell, T-cell lymphomas; HL, Hodgkin lymphoma; CNS, central nervous system; ASCT, autologous stem cell transplantation. CISL 0601, concurrent chemo-radiotherapy (CCRT) and weekly cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone); CISL 0602, radioimmunotherapy with 131I-rituximab; CISL 0603, bortezomib plus CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) every 2 weeks; CISL 0604, alemtuzumab plus and DHAP (dexamethasone, high-dose cytarabine, and cisplatin); CISL 0605, rituximab (R) plus CVP (cyclophosphamide, vincristine, and prednisolone); CISL 0606, gemcitabine single agent; CISL 0607, yttrium-90 ibritumomab tiuxetan consolidation following rituximab plus CHOP; CISL 0701, bortezomib plus CHOP; CISL 0702, GIDOX (gemcitabine, ifosfamide, dexamethasone, and oxaliplatin); CISL 0801, CCRT followed by VIDL (etoposide, ifosfamide, dexamethasone, and L-asparaginase) with risk-based application of ASCT; CISL 0802, ESHAOX (etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin); CISL 0803, intensified 1st cycle R plus 8 cycles of R-CHOP, CISL 0806 and 0901, busulfan, melphalan, and etoposide as conditioning; CISL 0905, Ox-P (oxaliplatin and prednisolone); CISL 1001, high-dose methotrexate induction followed by alternative high-dose methotrexate and high-dose cytarabine combination consolidation; CISL 1003, GDP (gemcitabine, dexamethasone, and cisplatin); CISL 1004, R augmentation following R-CHOP induction; CISL 1006 and 1107, prospective cohort study with risk-adapted CNS and bone marrow evaluation; CISL 1008, CCRT followed by MIDLE (methotrexate, ifosfamide, dexamethasone, L-asparaginase, and etoposide); CISL 1009, R-CVP followed by R maintenance; CISL 1010, R-CVP; CISL 1011, ESHAOX (etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin); CISL 1106, R-CHOP and prophylactic intrathecal methotrexate; CISL 1108, everolimus plus CHOP; CISL 1201, vorinostat plus fludarabine, mitoxantrone, and dexamethasone; CISL 1205, comparison intravenous busulfan, melphalan, and etoposide versus intravenous busulfan, cyclophosphamide, and etoposide as conditioning regimen; CISL 1206, R plus reduced dose CHOP for elderly.

Reference

1. Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press;2008.

2. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008; 112:4384–4399. PMID: 19029456.

3. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012; 380:848–857. PMID: 22835603.

4. Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol. 2006; 85:781–786. PMID: 16847665.

5. Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol. 2007; 82:446–452. PMID: 17266060.

6. Oh SY, Kwon HC, Kim WS, et al. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Eur J Haematol. 2007; 79:287–291. PMID: 17692101.

7. Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett. 2007; 258:90–97. PMID: 17936499.

8. Oh SY, Kim WS, Kim SJ, et al. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol. 2009; 84:826–829. PMID: 19890833.

9. Oh SY, Kim WS, Kim JS, et al. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Int J Hematol. 2010; 92:510–517. PMID: 20838958.

10. Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010; 89:563–568. PMID: 20024551.

11. Oh SY, Kim WS, Kim JS, et al. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci. 2010; 101:2443–2447. PMID: 20831770.

12. Oh SY, Kim WS, Kim JS, et al. Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study. Acta Haematol. 2012; 127:100–104. PMID: 22178776.

13. Oh SY, Suh C. Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors. Korean J Intern Med. 2010; 25:227–236. PMID: 20830217.

14. Yhim HY, Kang HJ, Choi YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer. 2010; 10:321. PMID: 20569446.

15. Yhim HY, Kim JS, Kang HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012; 131:235–243. PMID: 21823120.

16. Kim SJ, Kang HJ, Kim JS, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011; 117:1958–1965. PMID: 21148334.

17. Kim YR, Kim JS, Min YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol. 2012; 5:49. PMID: 22889180.

18. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24:612–618. PMID: 16380410.

19. Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2010; 21:1058–1063. PMID: 19850636.

20. Ahn HK, Suh C, Chuang SS, et al. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012; 23:2703–2707. PMID: 22547542.

21. Kim YR, Kim JS, Kim SJ, et al. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011; 4:34. PMID: 21843362.

22. Kim SJ, Moon JH, Kim H, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012; 53:1515–1524. PMID: 22273250.

23. Yun J, Kim SJ, Won JH, et al. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res. 2010; 34:1175–1179. PMID: 20206997.

24. Kim SJ, Choi CW, Mun YC, et al. Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer. 2011; 11:321. PMID: 21798075.

25. Won YW, Kwon JH, Lee SI, et al. Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Ann Hematol. 2012; 91:223–233. PMID: 21789622.

26. Chang MH, Kim SJ, Kim K, et al. Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. Leuk Lymphoma. 2009; 50:1119–1125. PMID: 19557632.

27. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012; 91:543–551. PMID: 21922208.

28. Oh SY, Kim WS, Lee DH, et al. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs. 2010; 28:171–177. PMID: 19421710.

29. Kim JE, Yoon DH, Jang G, et al. A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. Korean J Hematol. 2012; 47:53–59. PMID: 22479278.

30. Yang DH, Kim WS, Kim SJ, et al. Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53:807–811. PMID: 22035417.

31. Sym SJ, Lee DH, Kang HJ, et al. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2009; 64:27–33. PMID: 18839172.

32. Park BB, Kim WS, Eom HS, et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest New Drugs. 2011; 29:154–160. PMID: 19756371.

33. Kang HJ, Lee SS, Kim KM, et al. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia Pac J Clin Oncol. 2011; 7:136–145. PMID: 21585693.

34. Kang HJ, Lee SS, Byun BH, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013; 71:945–953. PMID: 23370662.

35. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009; 27:6027–6032. PMID: 19884539.

36. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008; 19:2079–2083. PMID: 18689866.

37. Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012; 48:3223–3231. PMID: 22770877.

38. Kim SJ, Kim K, Kim BS, et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol. 2009; 20:390–392. PMID: 19211502.

39. Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH. Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2010; 45:801–802. PMID: 19767780.